
Mangoceuticals fell 88.3% from $1.14 to $0.13, behind the S&P 500's +5.7%. Its worst day was Mar 20 (−54.5%), and its low came Nov 19 at $0.13.
Nov 20, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Mangoceuticals closed at its highest level of the year, 14.9% above where the year started.
+7.4% · S&P 500 +0.5%
Story events cover the past 12 months · Times ET
Mangoceuticals shares rose 48.8%, while the S&P 500 rose 0.7%.
+48.8% · S&P 500 +0.7%
Mangoceuticals stock jumps despite no fresh news, as lawsuit dispute, TRT sales surge, and platform shift shape investor sentiment.
+99.8%, the year's best day · S&P 500 +1.1%
EPS of $-0.13 was reported on $94,360.00 revenue.
−6.1% · S&P 500 +0.1%
EPS of $-0.22 was reported on $67,864.00 revenue.
+3.4% · S&P 500 +1.0%
Mangoceuticals shares jumped 137.77% after hours following its definitive business combination agreement with Nuclea Energy.
+89.7%, on 512M shares, the year's heaviest volume · S&P 500 +0.7%
EPS of $-0.09 was reported on $68,757.00 revenue.
+0.2% · S&P 500 −0.2%
EPS of $-0.19 was reported on $69,503.00 revenue.
−0.2% · S&P 500 −1.0%
Where it ended: a close of $0.13 on Nov 19, 2026.
Nothing in the past 12 months.
All MGRX analyst actionsNothing in the past 12 months.
All MGRX dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MGRX and SPY from Benzinga historical bars. Not investment advice.